Details of Disease

General Information of Disease (ID: DISK4DFB)

• Disease Name: Hyperplasia
• Synonyms: hyperplastic; hyperplasia
• Definition: An abnormal increase in the number of cells in an organ or a tissue with consequent enlargement.
• Disease Hierarchy:
  DIS11CME: Cell proliferative disorder
  DISK4DFB: Hyperplasia
• Disease Identifiers:
  MONDO ID: MONDO_0005043
  MESH ID: D006965
  UMLS CUI: C0020507
  MedGen ID: 43784
  SNOMED CT ID: 76197007

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 34 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CSK	TTX6F0Q	Limited	Biomarker	[1]
HMOX1	TTI6V2A	Limited	Therapeutic	[2]
IL13	TT0GVCH	Limited	Biomarker	[3]
LEP	TTBJEZ5	Limited	Biomarker	[4]
OGG1	TTRU01G	Limited	Biomarker	[5]
TCF7L2	TT80QAL	Limited	Biomarker	[6]
IL9	TT0JTFD	moderate	Biomarker	[3]
KDM1A	TTNR0UQ	moderate	Biomarker	[7]
LDLR	TTH0DUS	moderate	Biomarker	[8]
NFE2L2	TTA6ZN2	moderate	Therapeutic	[2]
AKT1	TTWTSCV	Strong	Biomarker	[9]
BRD4	TTSRAOU	Strong	Biomarker	[10]
CCNB1	TT9P6OW	Strong	Biomarker	[11]
CCND1	TTFCJ7S	Strong	Biomarker	[12]
CDKN1A	TT9GUW0	Strong	Biomarker	[13]
GLP1R	TTVIMDE	Strong	Biomarker	[14]
HIF1A	TTSN6QU	Strong	Biomarker	[15]
HSPB1	TT9AZWY	Strong	Biomarker	[16]
HTR4	TT07C3Y	Strong	Altered Expression	[17]
IKBKB	TTJ3E9X	Strong	Biomarker	[18]
IRS2	TTF95B8	Strong	Altered Expression	[19]
LHCGR	TT2O4W9	Strong	Genetic Variation	[20]
MMP1	TTMX39J	Strong	Biomarker	[21]
MMP2	TTLM12X	Strong	Biomarker	[22]
MYCN	TT9JBY5	Strong	Biomarker	[23]
PAM	TTF4ZPC	Strong	Biomarker	[24]
PDE11A	TTTWC79	Strong	Biomarker	[25]
PRG4	TTSKF4V	Strong	Biomarker	[26]
PTGIR	TTOFYT1	Strong	Genetic Variation	[27]
RXRG	TTH029C	Strong	Biomarker	[28]
SCN9A	TT4G2JS	Strong	Altered Expression	[29]
STAR	TTEI40H	Strong	Genetic Variation	[30]
TGFBR2	TTZE3P7	Strong	Biomarker	[31]
TNFRSF13B	TTL9OD4	Strong	Genetic Variation	[32]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
MAT1A	DEQ6NC9	moderate	Biomarker	[33]
TPMT	DEFQ8VO	Strong	Genetic Variation	[34]

This Disease Is Related to 13 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CCN5	OTADU8JJ	Limited	Altered Expression	[35]
SCG5	OTXSJMT1	Limited	Altered Expression	[35]
COL2A1	OT5E59C8	moderate	Biomarker	[36]
KCNK1	OTBXPTKX	moderate	Therapeutic	[37]
MAPK6	OTDDNF3Q	moderate	Biomarker	[38]
ASCL1	OTI4X44G	Strong	Biomarker	[39]
INSL3	OT7KUNTE	Strong	Biomarker	[40]
IRS4	OTTOL40K	Strong	Genetic Variation	[41]
KRT75	OT28B9E6	Strong	Biomarker	[42]
RLN1	OTL6QNHG	Strong	Biomarker	[40]
RLN2	OTY3OG71	Strong	Biomarker	[40]
RLN3	OTQSQMUQ	Strong	Therapeutic	[43]
TNFRSF10D	OTOSRDJT	Strong	Biomarker	[44]

References

• [1] Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation.FEBS Lett. 2005 Jul 4;579(17):3497-502. doi: 10.1016/j.febslet.2005.05.030.
• [2] Sulfasalazine induces haem oxygenase-1 via ROS-dependent Nrf2 signalling, leading to control of neointimal hyperplasia.Cardiovasc Res. 2009 Jun 1;82(3):550-60. doi: 10.1093/cvr/cvp072. Epub 2009 Feb 21.
• [3] IL-9 promotes IL-13-dependent paneth cell hyperplasia and up-regulation of innate immunity mediators in intestinal mucosa.J Immunol. 2009 Apr 15;182(8):4737-43. doi: 10.4049/jimmunol.0801941.
• [4] In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice.J Biochem Mol Toxicol. 2017 Feb;31(2):10.1002/jbt.21840. doi: 10.1002/jbt.21840. Epub 2016 Oct 6.
• [5] Enhancement of lung carcinogenesis initiated with 4-(N-hydroxymethylnitrosamino)-1-(3-pyridyl)-1-butanone by Ogg1 gene deficiency in female, but not male, mice.J Toxicol Sci. 2009 Apr;34(2):163-74. doi: 10.2131/jts.34.163.
• [6] T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis.Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4914-9. doi: 10.1073/pnas.1102300108. Epub 2011 Mar 7.
• [7] Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer.PLoS One. 2012;7(4):e35065. doi: 10.1371/journal.pone.0035065. Epub 2012 Apr 6.
• [8] Hepatic hyperplasia and cancer in rats: metabolic alterations associated with cell growth.Gastroenterology. 1997 Jul;113(1):238-48. doi: 10.1016/s0016-5085(97)70101-x.
• [9] Nifedipine inhibits vascular smooth muscle cell dedifferentiation via downregulation of Akt signaling. Hypertension. 2010 Aug;56(2):247-52. doi: 10.1161/HYPERTENSIONAHA.110.149781. Epub 2010 Jun 7.
• [10] Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition.Cell Rep. 2014 Sep 25;8(6):1919-1929. doi: 10.1016/j.celrep.2014.08.025. Epub 2014 Sep 18.
• [11] Cellular distributions of molecules with altered expression specific to thyroid proliferative lesions developing in a rat thyroid carcinogenesis model.Cancer Sci. 2009 Apr;100(4):617-25. doi: 10.1111/j.1349-7006.2009.01094.x. Epub 2009 Feb 25.
• [12] Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.Calcif Tissue Int. 2011 Jul;89(1):29-35. doi: 10.1007/s00223-011-9490-4. Epub 2011 May 4.
• [13] Immunohistochemical cellular distribution of proteins related to M phase regulation in early proliferative lesions induced by tumor promotion in rat two-stage carcinogenesis models.Exp Toxicol Pathol. 2014 Jan;66(1):1-11. doi: 10.1016/j.etp.2013.07.001. Epub 2013 Jul 23.
• [14] On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice.Toxicol Pathol. 2013 Feb;41(2):303-9. doi: 10.1177/0192623312472402.
• [15] Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX.Virchows Arch. 2010 Jul;457(1):53-61. doi: 10.1007/s00428-010-0938-0. Epub 2010 Jun 5.
• [16] A novel cell permeant peptide inhibitor of MAPKAP kinase II inhibits intimal hyperplasia in a human saphenous vein organ culture model. J Vasc Surg. 2010 Dec;52(6):1596-607. doi: 10.1016/j.jvs.2010.06.168. Epub 2010 Sep 22.
• [17] Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome.J Clin Endocrinol Metab. 2003 Jan;88(1):248-54. doi: 10.1210/jc.2002-021107.
• [18] IKKbeta-dependent NF-kappaB pathway controls vascular inflammation and intimal hyperplasia.FASEB J. 2005 Aug;19(10):1293-5. doi: 10.1096/fj.04-2645fje. Epub 2005 Jun 6.
• [19] Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2.Mol Cell Biol. 2006 Dec;26(24):9302-14. doi: 10.1128/MCB.00260-06. Epub 2006 Oct 9.
• [20] A constitutively active somatic mutation of the human lutropin receptor found in Leydig cell tumors activates the same families of G proteins as germ line mutations associated with Leydig cell hyperplasia.Endocrinology. 2003 Sep;144(9):3872-8. doi: 10.1210/en.2003-0365.
• [21] Nanoparticle-mediated local delivery of an antisense TGF-1 construct inhibits intimal hyperplasia in autogenous vein grafts in rats.PLoS One. 2012;7(7):e41857. doi: 10.1371/journal.pone.0041857. Epub 2012 Jul 30.
• [22] Serum levels of matrix metalloproteinase-2 as a marker of intimal hyperplasia.J Surg Res. 2010 May 1;160(1):9-13. doi: 10.1016/j.jss.2009.04.003. Epub 2009 May 13.
• [23] A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene. 2015 Jun;34(26):3357-68. doi: 10.1038/onc.2014.269. Epub 2014 Sep 1.
• [24] Hyperplasia of alveolar neuroendocrine cells in rat lung carcinogenesis by silica with selective expression of proadrenomedullin-derived peptides and amidating enzymes.Lab Invest. 2001 Dec;81(12):1627-38. doi: 10.1038/labinvest.3780376.
• [25] Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.Clin Cancer Res. 2008 Jun 15;14(12):4016-24. doi: 10.1158/1078-0432.CCR-08-0106.
• [26] CACP, encoding a secreted proteoglycan, is mutated in camptodactyly-arthropathy-coxa vara-pericarditis syndrome. Nat Genet. 1999 Nov;23(3):319-22. doi: 10.1038/15496.
• [27] Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study.Pharmacogenet Genomics. 2008 Jul;18(7):611-20. doi: 10.1097/FPC.0b013e328301a774.
• [28] Immunohistochemical detection of the retinoid X receptors alpha, beta, and gamma in human prostate.J Androl. 2003 Jan-Feb;24(1):113-9.
• [29] Function and role of voltage-gated sodium channel NaV1.7 expressed in aortic smooth muscle cells.Am J Physiol Heart Circ Physiol. 2009 Jan;296(1):H211-9. doi: 10.1152/ajpheart.00960.2008. Epub 2008 Oct 31.
• [30] Role of a founder c.201_202delCT mutation and new phenotypic features of congenital lipoid adrenal hyperplasia in Palestinians.J Clin Endocrinol Metab. 2007 Oct;92(10):4000-8. doi: 10.1210/jc.2007-1306. Epub 2007 Jul 31.
• [31] In situ detection of TGF betas, TGF beta receptor II mRNA and telomerase activity in rat cholangiocarcinogenesis.World J Gastroenterol. 2003 Mar;9(3):590-4. doi: 10.3748/wjg.v9.i3.590.
• [32] Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes.J Allergy Clin Immunol. 2007 Nov;120(5):1178-85. doi: 10.1016/j.jaci.2007.10.001.
• [33] Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A.FASEB J. 2002 Aug;16(10):1292-4. doi: 10.1096/fj.02-0078fje. Epub 2002 Jun 7.
• [34] Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation.Liver Transpl. 2005 Jul;11(7):826-833. doi: 10.1002/lt.20377.
• [35] Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators.Oncogene. 2004 Feb 26;23(8):1575-85. doi: 10.1038/sj.onc.1207277.
• [36] Norisoboldine ameliorates collagen-induced arthritis through regulating the balance between Th17 and regulatory T cells in gut-associated lymphoid tissues.Toxicol Appl Pharmacol. 2015 Jan 1;282(1):90-9. doi: 10.1016/j.taap.2014.11.008. Epub 2014 Dec 3.
• [37] Nuclear receptor CAR specifically activates the two-pore K+ channel Kcnk1 gene in male mouse livers, which attenuates phenobarbital-induced hepatic hyperplasia.Toxicol Sci. 2013 Mar;132(1):151-61. doi: 10.1093/toxsci/kfs338. Epub 2013 Jan 4.
• [38] Early induction of cytokines/cytokine receptors and Cox2, and activation of NF-B in 4-nitroquinoline 1-oxide-induced murine oral cancer model.Toxicol Appl Pharmacol. 2012 Jul 15;262(2):107-16. doi: 10.1016/j.taap.2012.04.023. Epub 2012 Apr 25.
• [39] Vitamin A deficiency leads to increased cell proliferation in olfactory epithelium of mature rats.J Neurobiol. 2003 Mar;54(4):539-54. doi: 10.1002/neu.10192.
• [40] Human medullary thyroid carcinoma: a source and potential target for relaxin-like hormones.Ann N Y Acad Sci. 2005 May;1041:449-61. doi: 10.1196/annals.1282.069.
• [41] Selective alterations in insulin receptor substrates-1, -2 and -4 in theca but not granulosa cells from polycystic ovaries.Mol Hum Reprod. 2004 Jul;10(7):473-9. doi: 10.1093/molehr/gah066. Epub 2004 May 21.
• [42] The role of cytokeratin 5/6 as an adjunct diagnostic tool in breast core needle biopsies.Int J Surg Pathol. 2008 Oct;16(4):399-406. doi: 10.1177/1066896908316901. Epub 2008 May 21.
• [43] Effect of relaxin on myocardial ischemia injury induced by isoproterenol.Peptides. 2005 Sep;26(9):1632-9. doi: 10.1016/j.peptides.2005.02.008.
• [44] Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression.Mod Pathol. 2006 Oct;19(10):1339-43. doi: 10.1038/modpathol.3800655. Epub 2006 Jun 23.